InvestSMART

Lumos Diagnostics Holdings Limited (ASX: LDX) - Announcements

- Current share price for LDX : $0.115

ASX company news and announcements for Lumos Diagnostics Holdings Limited (LDX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Lumos Diagnostics Holdings Limited (LDX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Lumos Diagnostics Holdings Limited (LDX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Lumos Diagnostics Holdings Limited (LDX)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$109 Application for quotation of securities - LDX 21 Nov 2025 1:20PM $0.185 $0.115 fallen by 37.84%
$109 Lumos Secures 100% US Medicare Reimbursement for FebriDx 21 Nov 2025 1:17PM $0.185 $0.115 fallen by 37.84%
$109 Lumos Enters Strategic Collaboration with AcuityMD 20 Nov 2025 8:30AM $0.170 $0.115 fallen by 32.35%
$109 Notification regarding unquoted securities - LDX 12 Nov 2025 3:29PM $0.215 $0.115 fallen by 46.51%
$109 Application for quotation of securities - LDX 31 Oct 2025 4:34PM $0.205 $0.115 fallen by 43.90%
$109 Change of Director's Interest Notice - DW 31 Oct 2025 4:31PM $0.205 $0.115 fallen by 43.90%
$109 Notification regarding unquoted securities - LDX 31 Oct 2025 4:26PM $0.205 $0.115 fallen by 43.90%
$109 New Constitution 28 Oct 2025 4:32PM $0.200 $0.115 fallen by 42.50%
$109 Results of Annual General Meeting 24 Oct 2025 12:49PM $0.260 $0.115 fallen by 55.77%
$109 2025 AGM Presentation 24 Oct 2025 8:56AM $0.245 $0.115 fallen by 53.06%
$109 AGM Chair Address 24 Oct 2025 8:51AM $0.245 $0.115 fallen by 53.06%
$109 Quarterly Activities/Appendix 4C Cash Flow Report 23 Oct 2025 8:34AM $0.235 $0.115 fallen by 51.06%
$109 Lumos Commences FebriDx CLIA Waiver Pediatric Study 22 Oct 2025 9:35AM $0.235 $0.115 fallen by 51.06%
$109 Lumos Agreement with WellStreet Urgent Care for FebriDx 16 Oct 2025 9:34AM $0.165 $0.115 fallen by 30.30%
$109 Addendum to Notice of Annual General Meeting 13 Oct 2025 10:36AM $0.175 $0.115 fallen by 34.29%
$109 FebriDx UK Data Shows Reduced Antibiotic Use & Cost Savings 24 Sep 2025 3:31PM $0.155 $0.115 fallen by 25.81%
$109 ASX SMIDcaps 2025 Conference Presentation 24 Sep 2025 11:25AM $0.155 $0.115 fallen by 25.81%
$109 Notice of Annual General Meeting and Proxy Form 19 Sep 2025 3:58PM $0.158 $0.115 fallen by 26.98%
$109 Section 708A Cleansing Statement 15 Sep 2025 3:25PM $0.180 $0.115 fallen by 36.11%
$109 Application for quotation of securities - LDX 15 Sep 2025 3:23PM $0.180 $0.115 fallen by 36.11%
$109 Section 708A Cleansing Statement 11 Sep 2025 9:52AM $0.140 $0.115 fallen by 17.86%
$109 Application for quotation of securities - LDX 11 Sep 2025 9:50AM $0.140 $0.115 fallen by 17.86%
$109 Lumos Signs Second ANZ FebriDx Distribution Agreement 9 Sep 2025 2:53PM $0.140 $0.115 fallen by 17.86%
$109 Lumos Completes A$5.0 million Loan Facility 9 Sep 2025 2:10PM $0.140 $0.115 fallen by 17.86%
$109 Notification regarding unquoted securities - LDX 8 Sep 2025 4:25PM $0.150 $0.115 fallen by 23.33%

76 - 100 of 544 results

Page 4 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.